Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 6 Demographics and baseline characteristics of ‘earlier discharge’ population

From: Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials

 

Rezafungin

N = 15/93 (16%)

Caspofungin

N = 15/94 (16%)

All patients

N = 30/187 (16%)

Mean age (Years, SD)

52.3 (16.58)

60.6 (12.88)

56.5 (15.18)

Age >  = 18− < 65

10 (66.7%)

9 (60%)

19 (63%)

Male gender

8 (53.3%)

9 (60%)

17 (57%)

Initial diagnosis

   

Candidemia only

13 (86.7%)

12 (80%)

83%

Invasive candidiasis

2 (13.3%)

3 (20%)

17%

Top 3 represented risk factors

   

Broad-spectrum antibiotic therapy

11 (73.3%)

8 (53.3%)

19 (63.3%)

Central venous catheter

8 (53.3%)

9 (60%)

17 (56.7%)

Major surgery

8 (53.3%)

6 (40%)

14 (46.7%)

ICU involvement

   

ICU at any time

3 (20%)

5 (33.3%)

8 (26.7%)

ICU at randomisation

2 (13.3%)

5 (33.3%)

7 (23.3%)

Baseline Modified Apache II Score

   

 < 20

13 (86.7%)

12 (80%)

83%

 >  = 20

2 (13.3%)

3 (20%)

17%

  1. ICU, intensive care unit; SD, standard deviation